Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
21.06 (1y: -11%)
Market Cap 2.91 B P/E(ttm)
Enterprise Value 3 B P/B
INCY- NAS (USA)
Incyte Corp Ltd
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$21.06
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry		 vs
history
Cash to Debt 0.35
INCY's Cash to Debt is ranked higher than
57% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. INCY: 0.35 )
INCY' s 10-Year Cash to Debt Range
Min: 0.35   Max: 334.5
Current: 0.35
0.35
334.5
Equity to Asset -0.53
INCY's Equity to Asset is ranked lower than
62% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. INCY: -0.53 )
INCY' s 10-Year Equity to Asset Range
Min: -0.95   Max: 0.77
Current: -0.53
-0.95
0.77
F-Score: 3
Z-Score: -2.44
M-Score: -2.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) 0.40
INCY's Operating margin (%) is ranked higher than
82% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. INCY: 0.40 )
INCY' s 10-Year Operating margin (%) Range
Min: -4064.5   Max: 8.3
Current: 0.4
-4064.5
8.3
Net-margin (%) -14.9
INCY's Net-margin (%) is ranked higher than
64% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. INCY: -14.9 )
INCY' s 10-Year Net-margin (%) Range
Min: -4565.5   Max: -14.9
Current: -14.9
-4565.5
-14.9
ROA (%) -13.4
INCY's ROA (%) is ranked higher than
59% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. INCY: -13.4 )
INCY' s 10-Year ROA (%) Range
Min: -77   Max: -3.4
Current: -13.4
-77
-3.4
ROC (Joel Greenblatt) (%) 0.40
INCY's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: 0.40 )
INCY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -256.2   Max: 0.4
Current: 0.4
-256.2
0.4
Revenue Growth (%) 124.6
INCY's Revenue Growth (%) is ranked higher than
100% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: 124.6 )
INCY' s 10-Year Revenue Growth (%) Range
Min: -51.1   Max: 124.6
Current: 124.6
-51.1
124.6
EPS Growth (%) -36.3
INCY's EPS Growth (%) is ranked lower than
59% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: -36.3 )
INCY' s 10-Year EPS Growth (%) Range
Min: -36.3   Max: 49.2
Current: -36.3
-36.3
49.2
» INCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

INCY Guru Trades in Q2 2012

Jim Simons 137,700 sh (New)
Steven Cohen 264,520 sh (+55.14%)
Pioneer Investments 212,730 sh (+1.92%)
Louis Moore Bacon Sold Out
» More
Q3 2012

INCY Guru Trades in Q3 2012

Manning & Napier Advisors, Inc 596,690 sh (New)
Pioneer Investments 212,920 sh (+0.09%)
Jim Simons Sold Out
Steven Cohen 19,507 sh (-92.63%)
» More
Q4 2012

INCY Guru Trades in Q4 2012

Jim Simons 246,900 sh (New)
Manning & Napier Advisors, Inc 745,870 sh (+25%)
Steven Cohen 22,800 sh (+16.88%)
Pioneer Investments Sold Out
» More
Q1 2013

INCY Guru Trades in Q1 2013

Vanguard Health Care Fund 3,133,100 sh (New)
Manning & Napier Advisors, Inc 790,270 sh (+5.95%)
Steven Cohen 15,678 sh (-31.24%)
Jim Simons 84,200 sh (-65.9%)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2013-03-31 New Buy0.29%$16.61 - $24.95 $ 21.063%3133100
George Soros 2011-03-31 Sold Out $13.37 - $16.56 $ 21.0643%0
George Soros 2010-12-31 New Buy$14.51 - $17.17 $ 21.0631%15000
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/S 8.35
INCY's P/S is ranked higher than
66% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. INCY: 8.35 )
INCY' s 10-Year P/S Range
Min: 1.64   Max: 209.75
Current: 8.35
1.64
209.75
EV-to-EBIT 100
INCY's EV-to-EBIT is ranked lower than
61% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. INCY: 100 )
INCY' s 10-Year EV-to-EBIT Range
Min: 87.6   Max: 2896.5
Current: 100
87.6
2896.5

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 55.4
INCY's Price/Net Current Asset Value is ranked higher than
63% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: 45.80 vs. INCY: 55.4 )
INCY' s 10-Year Price/Net Current Asset Value Range
Min: 7.9   Max: 828
Current: 55.4
7.9
828
Price/Median PS Value 0.5
INCY's Price/Median PS Value is ranked higher than
91% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. INCY: 0.5 )
INCY' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 5.8
Current: 0.5
0.2
5.8
Earnings Yield (Greenblatt) 1.00
INCY's Earnings Yield (Greenblatt) is ranked higher than
76% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: 1.00 )
INCY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 1.1
Current: 1
0.7
1.1
Forward Rate of Return (Yacktman) -2.5
INCY's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: -2.5 )
INCY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.9   Max: -2.6
Current: -2.5
-4.9
-2.6

Business Description

Incyte Corp Ltd was incorporated in Delaware in 1991. Incyte is a biopharmaceutical company focuses on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs. The Company's most advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor that was recently approved by the U.S. Food and Drug Administration (FDA) as a treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. MF is a serious, life-threatening blood cancer that belongs to a group of diseases known as myeloproliferative neoplasms that include polycythemia vera and essential thrombocythemia. JAKAFI is the first FDA-approved JAK inhibitor, and is part of a potentially important new oral drug class to treat cancer and chronic inflammatory diseases. The JAK pathway, which consists of four tyrosine kinases—JAK1, JAK2, JAK3 and Tyk2, is dysregulated in many oncologic and inflammatory conditions. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company. The Company's drug discovery and development activities face, and will continue to face, intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its product candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:ICY.Germany
» More Articles for INCY

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE May 14 2012 
Weekly Top Insider Buys: VTR, INCY, FULT, HMA, CMC Jan 23 2012 
04 stocks with insider buying of more than $1.5 million since beginning of 2012 Jan 22 2012 
Weekly CFO Sales Highlight: EPIQ, INCY, AVB, JOSB, PCS, FLO Jun 12 2011 
Incyte Corp. Reports Operating Results (10-Q) Aug 05 2010 
Weekly CEO Buys Highlight: Saul Centers Inc, China Marine Food Group Ltd, NL Industries Inc, Incyte Jul 11 2010 
Weekly CFO Buys Highlight: MFRI Inc., Uranerz Energy Corp., The Pep BoysManny Moe & Jack, DRI Corp., Jul 11 2010 
Weekly highlight of top insider buys: Medtronic Inc., Van Kampen Senior Income Trust, Incyte Corp., Jul 10 2010 
Incyte Corp. (INCY) CEO Paul A Friedman buys 10,000 Shares Jul 06 2010 
Incyte Corp. (INCY) CFO David C Hastings buys 2,000 Shares Jul 06 2010 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK